Solid Tumor
Solid Tumor 24
A Phase 1 Study of EPZ-6438 (an EZH2 Inhibitor) in Pediatric Patients with Relapsed/Refractory INI1-Negative Tumors or Synovial Sarcomas
A Phase I/II Study of the Oral TRK Inhibitor LOXO 101 in Pediatric Patients with Advanced Solid or Primary Central Nervous System Tumors
INFORM2 exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies
Pilot study of nivolumab in paediatric patients with hypermutant cancers
A Pivotal Phase 2 Trial of Antibody Naxitamab (hu3F8) and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone/Bone Marrow
Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Durvalumab Monotherapy or Durvalumab in Combination with Tremelimumab in Pediatric Patients with Advanced Solid Tumors and Hematological Malignancies
A Phase I, Open-label, Parallel Group Study to Investigate Olaparib Safety and Tolerability, Efficacy and Pharmacokinetics in Paediatric Patients (aged 6 months to 17 years) with Solid Tumours
PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION AND EXPANSION STUDY OF ENTRECTINIB (RXDX-101) IN CHILDREN AND ADOLESCENTS WITH NO CURATIVE FIRST-LINE TREATMENT OPTION, RECURRENT OR REFRACTORY SOLID TUMORS AND PRIMARY CNS TUMORS